Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

This study is testing a treatment using donor Natural Killer (NK) immune cells engineered to target a protein called CLL1, which is found on the surface of leukemia cells in acute myeloid leukemia (AML). AML is a fast-growing cancer of the blood and bone marrow. This is a cell therapy approach — using donor immune cells to attack the cancer. **You may be eligible if...** - You are 18 or older with relapsed or treatment-resistant AML - Your AML cells test positive for the CLL1 protein - Your overall health and organ function (heart, kidneys, liver) are adequate **You may NOT be eligible if...** - You have acute promyelocytic leukemia (APL, a specific subtype) - You have active leukemia in the central nervous system (brain/spinal fluid) - You have HIV, active hepatitis B or C - You have had a prior stem cell transplant - You have had recent heart problems, uncontrolled blood pressure, or lung disease Talk to your doctor to see if this trial is right for you.